{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ab54c70bb6ddf45527e06b1/641c5fc862f89600114d0ceb?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"After Years of Trial and Error, Biotech is Seeing More Successes Than Ever","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5ab54c70bb6ddf45527e06b1/1678134674936-9a1b3e831b9d720fedb988f5271ee3fb.jpeg?height=200","description":"<p>John Crowley, Chairman &amp; Former CEO of Amicus Therapeutics, joins the show to discuss the strides the biotech industry has made in therapies for rare genetic diseases and the industry landscape going forward. </p><p><br></p><p>This interview originally aired as part of Wharton Business Daily's Business of Healthcare special.</p>","author_name":"The Wharton School"}